Cilengitide
Childhood Cerebellar Astrocytic Neoplasm
Floatz Rating
B58/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00679354CT.gov Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | — | Completed | — | — | — |
NCT00063973CT.gov Cilengitide in Treating Children With Refractory Primary Brain Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Cerebellar Astrocytic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cilengitide (this asset) | National Cancer Institute (NCI) | P2 | B · 58 |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | B |
| Nivestim | City of Hope Medical Center | P1 | CCC |
| Dexasone | National Cancer Institute (NCI) | P1 | CCC |
| Romidepsin | City of Hope Medical Center | P1 | CCC |
| Vorinostat | National Cancer Institute (NCI) | P1 | CCC |
| o6-benzylguanine | National Cancer Institute (NCI) | P1 | CC |
+11 more in the Childhood Cerebellar Astrocytic Neoplasm cohort
Other indications for Cilengitide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Giant Cell Glioblastoma | — | P2 | B · 61 |
| Adult Glioblastoma | — | P2 | B · 61 |
| Gliosarcoma | — | P2 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IrinotecanNational Cancer Institute (NCI)BB
- OxaliplatinNational Cancer Institute (NCI)B
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)B
- NivestimCity of Hope Medical CenterCCC
- DexasoneNational Cancer Institute (NCI)CCC
Citation
Floatz Terminal. Cilengitide in Childhood Cerebellar Astrocytic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cilengitide-childhood-cerebellar-astrocytic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →